Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam
Cross Sectional Study to Evaluate the Acceptability of Oral Solution of Levetiracetam (Keppra®) (SOLUCION Study)
Sponsor: UCB Pharma
This observational or N/A phase trial investigates Epilepsy and is currently completed. UCB Pharma leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Jan 2017 — Apr 2018 [monthly]
Completed PHASE4
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- UCB Pharma
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alcalá de Henares, Spain , Alcorcón, Spain , Alcázar de San Juan, Spain , Alicante, Spain , Alzira Valencia, Spain , Badajoz, Spain , Barcelona, Spain , Benidorm, Spain , Cadz, Spain and 44 more locations